Alopecia Universalis With IL-12-RB1 and STAT4 Mutations Effectively Treated With Upadacitinib

A 9-year-old boy with alopecia universalis (AU) and atopic dermatitis, carrying IL-12-RB1 and STAT4 mutations, experienced full hair regrowth after 6 months of treatment with upadacitinib, a Janus kinase inhibitor (JAKi). This case highlights the potential of upadacitinib as an effective treatment for children with severe AU, particularly those with specific genetic mutations affecting the JAK-STAT pathway. The report underscores the importance of genetic testing in identifying suitable candidates for targeted therapies in pediatric patients with recalcitrant AU. Further research into genetic profiles may reveal additional therapeutic targets and improve understanding of the immune processes involved in AU.